Although a small number of studies have claimed that there are some endogenous anti-β2GP1 antibodies that target domains II-IV, pathological antibodies to β2GP1 isolated from human APS patients only interact with domain I (31). This evidence concerns the gene APOH and autoimmune polyendocrinopathy.